INTRODUCTION
Segmental defects of the vertebrae (SDV) are a relatively common congenital malformation (estimated at 0.5-1 per 1000 live births) (1) , and can present as a wide variety of radiological features, including uneven or fused vertebrae as well as rib malalignment, fusion or absence (2) . Such defects arise as a result of a disruption of embryonic developmental patterning, rather than a defect in bone formation (3) . In the developing embryo, the vertebral precursor tissues, somites, are regular repeated structures that arise from the unsegmented presomitic mesoderm (PSM) via a process called somitogenesis. The formation of segments is complex, and is controlled by the interplay of four signal transduction pathways (4) . In particular, the NOTCH signaling pathway and its regulators are critical for the coordination of this process, and disruption of many genetic elements of this pathway in the mouse leads to SDV identical to forms of spondylocostal dysostosis (SCD) in the human (3) . In the caudal PSM, oscillations of NOTCH activity and the bHLH protein HES7 generate traveling waves of gene expression. Cells in this region are prevented from differentiation by FGF and WNT signaling. In the rostral PSM, NOTCH activity is stabilized and cells differentiate to form segmental borders at regular time intervals (every 2 h in the mouse and 4 -6 h in humans) (5, 6) . † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors. The familial forms of SDV for which a genetic cause has been determined to date fall broadly into two groups. The first group, encompassing cases of severe SDV in which 10 or more contiguous vertebrae are malformed, is generally inherited in an autosomal recessive manner with complete penetrance. These include four forms of SCD caused by mutations in DLL3 (7) (SCD1; OMIM 277300), MESP2 (8) (SCD2; OMIM 608681), LFNG (9) (SCD3; OMIM 609813) and HES7 (10) (SCD4; OMIM 613686), and the phenotypically distinct syndrome spondylothoracic dysostosis, also caused by mutations in MESP2 (11) . Autosomal dominant inheritance of SCD has been reported; however, no gene mutations have been identified (12) (13) (14) (15) . The second group encompasses cases of SDV in which only a few vertebrae are affected, and have been shown to be due to haploinsufficiency with variable penetrance. These include cases of autosomal dominant Klippel -Feil syndrome, caused by mutations in GDF6 (16) (KFS1; OMIM 118100) or GDF3 (17) (KFS3; OMIM 613702), and cases of congenital scoliosis caused by mutation in MESP2 or HES7 (18) . In the latter case, there is evidence that environmental factors influence the penetrance of the phenotype (18) .
RESULTS
We used whole-exome sequencing to investigate a previously described three-generation Macedonian family comprising three SCD-affected individuals and exhibiting autosomal dominant inheritance (12) . Each individual had scoliosis, and short stature (≤1st percentile) due to severe shortening of the trunk from SDV throughout the spine, including hemivertebrae and fused vertebral blocks (12) (Fig. 1) . Since no additional abnormalities were detected, these cases represent non-syndromic SCD. In addition, in generation II of this family, there were six infant deaths from unknown cause(s) of whom we have no further phenotype information. Analysis of genomic DNA samples from the three affected individuals did not identify any abnormal sequence changes in the four known SCD genes (DLL3, MESP2, LFNG or HES7) (12) .
We performed whole-exome sequencing in five members of the family, three of whom had clinical features and radiographic evidence of SCD, and two of whom were clinically unaffected (Fig. 2 ). An average of 6.846 Gb of sequence per individual (range 3.98 -8.78 Gb) was generated, with mean on-target (exons + 200 bp) coverage of 75.0%. Mean depth of exomic coverage was 50-fold (range 37.0 -60.5), with 86.9 and 81.3% achieving 10-fold and 15-fold coverage, respectively (see Supplementary Material, Table S1 for mapping and coverage statistics, and detailed base calling statistics). Given the disease segregation within the family, we postulated that an autosomal dominant inheritance pattern was the most likely mode of inheritance. We therefore analyzed the data for heterozygous carriage of a single novel nonsynonymous SNP predicted to be not benign according to PolyPhen and shared by all affected individuals but not present in the unaffected individuals. After quality filtering, six potentially disease-causative SNPs remained in ECT2L, C9orf91, STK32C, KIRREL3, RNF6 and TBX6. All SNPs affected evolutionarily conserved bases with genomic evolutionary rate profiling [GERP (19) ] scores .4.0 (Table 1) . Of these six candidate genes, TBX6 (T-box transcription factor 6) was selected for further investigation, as it is the only gene associated with development of the vertebral column. Studies of mouse embryos have shown that TBX6 is a critical component of the somitogenesis machinery, with multiple roles in this process. It is expressed in the primitive streak, tailbud and PSM (20) . The classical mouse mutant rib-vertebrae [rv (21) ] is a hypomorphic allele of Tbx6 (22, 23) and has a phenotype highly reminiscent of SCD, with fused vertebral bodies, and rib fusions and bifurcations. Embryos homozygous for a Tbx6 null allele die around embryonic day (E) 10.5; they form up to nine irregular somites and caudal to this entirely lack somites with the paraxial mesoderm replaced by neural tube-like structures (24) . Likewise, in zebrafish, the tbx6/fused somites (fss) gene is required for the formation of somites throughout the trunk and tail, and for the development of anterior half-somite identity (25) (26) (27) . TBX6 directly binds to the promoter of the Notch ligand Dll1, and in combination with WNT signaling activates the expression of Dll1 throughout the PSM (28, 29) , a key requirement for the cyclical activation of NOTCH signaling. In addition, TBX6 directly activates the transcription of Mesp2 and Ripply2 in the rostral PSM (30) (31) (32) . These proteins are required for correct positioning of the segmental boundary.
We used Sanger sequencing to validate the TBX6 sequence variant and determine its segregation within all available family members. As expected, affected individuals tested were heterozygous for the TBX6 mutation, whereas unaffected individuals tested were homozygous wild-type (Fig. 2) . The sequence variant detected in this family disrupts the natural stop codon (c.1311A.T), which is predicted to result in the addition of 81 nonsense amino acids to the C-terminus (p.
* 437Cext * 81). The region comprising the stop codon and immediately upstream is highly evolutionarily conserved (with the affected base having a GERP score of 4.69), suggesting an essential function. To determine the functional consequences of this change, we used a previously published in vitro transcriptional activation assay to compare the wild-type and mutant TBX6 proteins (Fig. 3) . Among the multiple roles of TBX6 in somitogenesis, the protein activates expression of the Mesp2 gene by directly binding to cis-regulatory elements upstream of the transcription start site (30) . Cultured cells were co-transfected with an expression plasmid encoding TBX6 and a reporter plasmid consisting of a 356 bp fragment of the Mesp2 promoter (including two TBX6-binding sites) cloned upstream of the luciferase coding region. In this system, wild-type TBX6 was able to induce an 6-fold increase in transcription over baseline (Fig. 3A, compare lanes  1 and 2) . By contrast, the transcriptional activation activity of the mutant TBX6 protein was statistically significantly impaired, 50% of wild-type (Fig. 3A, compare lanes 2 and  3) . Since the phenotype was dominant, we investigated whether the mutant protein was acting in a dominant negative manner. We repeated the transcription activation assay simultaneously transfecting equal amounts of wild-type and mutant plasmids. This resulted in a level of transcription activation that was intermediate between the wild-type alone and mutant alone (Fig. 3A, lane 4) . Thus, the TBX6 mutant protein does not appear to act as a dominant negative. Thus, it is likely that the patient phenotype is the result of haploinsufficiency.
As the reduced function of the mutant TBX6 protein could be due to alteration of its translation efficiency or protein stability, we therefore next investigated the relative expression levels of wild-type and mutant protein in cell culture. Since no commercial antibody was available, we added an in-frame HA tag to the N-terminus of both wild-type and mutant TBX6 constructs. These were transfected into C2C12 cells, harvested 24 h later and whole-cell extracts analyzed by western blot (Fig. 3B) . The observed sizes of the HA-tagged wild-type and mutant TBX6 proteins (55 and 65 kDa, respectively) were slightly larger than expected (48.4 and 56.9 kDa), perhaps indicating post-translation modification. However, there was no difference in relative expression levels, suggesting that the reduction in transcriptional activation activity of the mutant TBX6 protein was entirely due to the additional 81 nonsense C-terminal amino acids. In this family, the severe vertebral phenotype is dominant, whereas in the mouse no phenotype had been previously reported for heterozygous embryos carrying either the null or hypomorphic alleles (21, 24) . However, we have previously identified vertebral defects in embryos heterozygous for null alleles of NOTCH pathway genes involved in somitogenesis originally reported as having no phenotype (18) . We therefore sought to re-examine the vertebral phenotype of E14.5 embryos heterozygous for the null Tbx6 allele (Tbx6 tmPa1 ).
Tbx6
+/2 mice were either intercrossed or crossed with Tbx6 +/+ mice and embryos harvested at E14.5. The developing skeletons of these embryos were then stained using alcian blue as previously described (18) . In heterozygous embryos, we found a mild cervical vertebral defect in 26 of 56 and a sacral defect in 17 of 56, whereas no defects were apparent in 32 wildtype embryos (Fig. 4A) . In the cervical region, abnormalities were restricted to the axis and atlas. These included vertebrae in which the distal part of the spinous process was not attached to the rest of the spinous process ( Fig. 4C and E) , and vertebrae in which foramen were present in the most distal portion of the spinous processes (Fig. 4D ). In addition, there were occasional threads of cartilage leading from spinous process of axis to the atlas (not shown). Similar defects were noted in the sacral vertebrae (not shown).
DISCUSSION
The identification of a deleterious mutation in TBX6 is, we believe, the first identification of the cause of an autosomal dominant case of SCD. Our studies show that the mutation resulted in haploinsufficiency of TBX6, with available evidence suggesting complete penetrance of the severe vertebral phenotype. This is in contrast to previous studies of individuals with vertebral defects that identified heterozygous deleterious mutations in genes including GDF3, GDF6, MESP2 or HES7 (16 -18) . In all of these cases, the vertebral defects were mild, not fulfilling SCD criteria, and there was incomplete penetrance of the phenotype.
This study is also one of only few studies in the literature to have mapped the causative gene for an autosomal dominant disease by exome sequencing only within a single kindred (33 -40) . The most powerful mapping strategy within kindreds is to sequence individuals separated by the greatest number of meiotic events. However, in this kindred, DNA was only available from a small number of surviving individuals over only two generations, with few meiosis separating affected and unaffected individuals. By chance, the probability of any particular SNP segregating with disease status within the sequenced individuals was 1/2 4 . Although we identified a mean of more than 24 000 SNPs per individual after QC, the number of novel, good quality reads predicted to be damaging was reduced to a mean of only 47 SNPs per individual; of these, only 6 fitted the Mendelian model of inheritance observed in the family. Of these, TBX6 had strong a priori evidence supporting a role for mutations in this gene being responsible for SCD in this family, which hypothesis was subsequently validated by the functional work described. We used a proteinprediction algorithm to filter the results to exclude changes predicted to have a benign effect on function. However, if we excluded this filtering step, the total number of candidate genes was increased only very modestly, by four, none of which had similarly strong a priori support for a role in SCD.
In conclusion, this study identifies for the first time a genetic lesion causing autosomal dominant SCD, and demonstrates in vitro that this most likely operates by haploinsufficiency. The finding that mutation of TBX6 associates with congenital vertebral anomalies in humans is also novel. In addition to its role in causing AD SCD, TBX6 must also be considered to be a candidate gene for causing autosomal recessive SCD, as well as cases of mild SDV. This study, combining sequencing-based gene-mapping studies with studies in genetically modified animals and in vitro studies of functional effects of identified sequence variants, provides a model for gene-mapping studies in situations where insufficient clinical material precludes precise identification of the disease-causative mutation by genetic approaches alone. The six remaining genes containing SNPs were ECT2L, C9orf91, STK32C, KIRREL3, RNF6 and TBX6. All of these SNPs were in conserved areas (GERP score .4.0). Affected individuals are indicated by asterisks.
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MATERIALS AND METHODS

Ethics statement
The study was approved by the St Vincent's Hospital Human Research Ethics Committee (approval H05/057), and all subjects or their respective guardians gave informed written consent. Animal experiments were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh (Animal Welfare Assurance Number: A3187-01).
Whole-exome sequencing
Genomic DNA was extracted from peripheral blood, using standard protocols, and 5 mg was used to construct DNA sequencing libraries, using a sample preparation kit for paired-end sequencing (Illumina) as per the manufacturer's protocol. Liquid-phase hybridization for exome capture was performed using Nimblegen SeqCap EZ Exome Library v1.0 kits (Roche) for individual III.2 and TruSeq Exome Enrichment Kit v2.0 (Illumina) for the remaining four samples. Efficiency of sequence capture was assessed using quantitative real-time PCR with standard control primers as recommended by the manufacturer. Each DNA sequencing library was quality-checked and quantified using a 2100 Bioanalyzer and DNA 1000 chip kits (Agilent); and DNA concentration was standardized to 10 nM for sequencing. Massive parallel sequencing was performed using a 56 paired-end read sequencing protocol on a single-flow cell lane of an Illumina Genome Analyzer II sequencer for individual III.2, and using a 100 paired-end read as multiplexed samples on a flow cell lane of an Illumina HiSeq 2000 sequencer for the remaining samples. In all cases, the manufacturers' reagents were used. Initial base calling was performed using the CASAVA 1.7 data analysis pipeline software (Illumina). Sequence data were aligned to the current build of the human genome (hg19, released 
Whole-exome sequencing data analysis
Sequencing data were analyzed and filtered using custom scripts employing R and Bioconductor. Good quality SNPs and indels were retained (minimum depth of coverage for SNP calling was set at .10-fold for homozygous SNPs, .15-fold for heterozygous SNPs). Additionally, GATKprovided quality parameters were used, with the inclusion of SNPs/indels with the following values QUAL . 50, QD . 0.5, HRUN , 5 and SB , 0.1 (QUAL, combined recalibrated quality score at the SNP position; DP, sequencing depth at the SNP position; QD, QUAL/DP ratio at the SNP position; HRun, maximal length of the homopolymer run; SB, strand bias at the SNP position). SNPs and indels were retained according to the prediction of potentially damaging consequence ('nonsynonymous single nucleotide variant (SNV)', 'splicing', 'frameshift substitution', 'stopgain SNV', 'stoploss SNV'), using both RefSeq and UCSC transcripts. Further filtering excluded SNPs observed in NCBI dbSNP (release 132), 1000 Genomes, 1000 Genomes small indels [called using the DINDEL program (45) ], the SNPs of 46Genomes release by Complete Genomics and other whole exomes from control samples run internally using similar capture technology. We also filtered on predicted effect on protein function, using PolyPhen (genetics.bwh.harvard.edu/pph/).
Sanger sequencing
A 466 bp fragment containing the identified SNP was amplified by PCR, using the following primers: 5 ′ -AGTGGGAC AGGGGACCAG-3 ′ and 5 ′ -TTAGGCTTTGAAGCCAGAGG-3 ′ . Sequencing of both strands was performed with BigDye v3.1 cycle sequencing reagents (Applied Biosystems), and capillary electrophoresis was performed on a 3730 DNA Analyzer (Applied Biosystems) at the Ramaciotti Centre for Gene Function Analysis and the University of Queensland Diamantina Institute.
In vitro transcription assay
We obtained a full-length cDNA clone of human TBX6 (Open Biosystems clone 5460190). A PCR fragment containing the full cDNA was cloned into the expression vector pCMX (46) . Site-directed mutagenesis was used to create the stoploss mutation. Mouse muscle satellite C2C12 cells (47, 48) were grown in high-glucose DMEM (Life Technologies) containing 10% FCS (Life Technologies). Transfections were performed using Lipofectaminew LTX and PLUS TM reagent (Life Technologies) in 12-well trays. Cells were co-transfected with plasmids encoding wild-type or mutant TBX6, and firefly [pGL3-P2Ewt (30)] and Renilla (SV40 promoter) luciferase reporters. Cells were harvested in 250 ml of Passive Lysis Buffer (Promega) 24 h after transfection. Firefly and Renilla luciferase activities were assayed using the Dual-Luciferase reporter system (Promega) and measured on a FLUOstar Optima Luminometer (BMG). Firefly luciferase counts were normalized against Renilla luciferase counts to account for differences in transfection efficiency. One-way ANOVA was performed on data from four independent experiments. Significance was determined using Tukey's post hoc test.
Western blots
In-frame HA tags were added to the N-terminus of both wildtype and mutant TBX6 constructs, using PCR mutagenesis. Tagged constructs were transfected into C2C12 cells with Lipofectaminew LTX and PLUS TM reagent (Life Technologies) in 60 mm dishes, and harvested 24 h later. Western blot analysis was performed on whole-cell extracts by standard methods, using mouse monoclonal anti-HA (Covance) and goat anti-beta tubulin (Abcam) primary antibodies, with IRDye 800 donkey anti-mouse (LI-COR Biosciences) and AlexaFluor 680 donkey anti-goat (Invitrogen) secondary antibodies. Blots were imaged using an Odyssey Infrared Imaging System (LI-COR Biosciences).
